logo_web
  • Clinical Trials
    • Management of medication
    • Management of reimbursement of expenses to patients
    • Supply of medical devices
    • Destruction
    • Calibration of medical devices
    • Import and labeling of medication
    • Masking. Placebos manufacturing
  • Blog
  • Quality
    • Certifications
    • RSE
  • Clients
  • Patient Reimbursement Forms
    • Validation / Expense Reimbursement Sheet
✕
  • Clinical Trials
    • Management of medication
    • Management of reimbursement of expenses to patients
    • Supply of medical devices
    • Destruction
    • Calibration of medical devices
    • Import and labeling of medication
    • Masking. Placebos manufacturing
  • Blog
  • Quality
    • Certifications
    • RSE
  • Clients
  • Patient Reimbursement Forms
    • Validation / Expense Reimbursement Sheet

ISCIII will represent Spain in the largest research appointment in Europe

Source: redaccionmedica.com

The director of the Health Institute Carlos III (ISCIII), Raquel Yotti Álvarez, in charge of the head of the Spanish delegation at the opening ceremony of the ‘EU-Openscreen ERIC’, which will take place in Berlin (Germany) next Tuesday, the 25th of September.

Spain is one of the seven founding members of this new consortium of European research infrastructure (ERIC), launched by the European Commission last April and also involving the Czech Republic, Finland, Germany, Latvia, Norway and Poland

In addition, Denmark is expected to become a full member by 2019 and other countries are preparing their ‘EU-Openscreen ERIC’ participation, integrate high-capacity platforms across Europe and offer researchers in Europe, and the rest of the world, open access to an exceptionally wide range of high technology and tools for the archiving of chemical articles for their biological effects.

The general objective of this European infrastructure is to provide the scientific community with the possibility of accessing information, experience and technical capabilities of high interest for research related to chemical compounds, knowledge of biological interactions and the discovery of new drugs, all of them currently not available to most European researchers.

Another of its goals is to respond to these limitations by focusing its operation on three essential elements: a centralized chemical compound library, a network of screening platforms and centers specialized in pharmaceutical chemistry, and an open access database that will collect the results of these chemical-biological interactions.

Leader in the investigation of the peninsula

Specifically, Spain brings to the initiative a network of research centers integrated by the Príncipe Felipe Research Center of the Valencian Community, the Hospital del Mar Institute for Medical Research of Barcelona; the MEDINA Foundation of Granada and the University of Santiago de Compostela. These four centers are part of the REDEFAR Spanish Drug Discovery Network, which currently provides two of the eight European high-capacity screening centers.

In addition, the platforms integrated in ‘EU-Openscreen’ jointly use a collection, rationally selected, comprising up to 140,000 compounds, patented and commercial, from the research of European chemists. This access will facilitate quality research on the molecular mechanisms of biological processes and the application of new knowledge to generate innovative solutions in the fields of health, nutrition and the environment.

In Distefar we are sure that the development of the act will be a success.

Related entries

2 October, 2023

Decentralisation of trials, networking and digitisation, proposals to improve patient participation in clinical research


Leer más
26 September, 2023

More than 120 molecules in Alzheimer’s research, the great hope for patients, families and society


Leer más
19 September, 2023

The pharmaceutical industry’s plan to expand clinical trials in primary care


Leer más

Recent Posts

  • Decentralisation of trials, networking and digitisation, proposals to improve patient participation in clinical research
  • More than 120 molecules in Alzheimer’s research, the great hope for patients, families and society
  • The pharmaceutical industry’s plan to expand clinical trials in primary care
  • Health commitment to the pharmaceutical industry’s Strategic Plan to avoid losing 8,000 million euros
  • Improving patient access to innovative medicines and boosting R&D and manufacturing in Spain are the main priorities of the pharmaceutical industry

Contacta con nosotros


Tfno: +34 955.77.67.67
Fax: +34 955.77.65.56
info@distefar.net


Distefar del Sur
Sede Central

Distefar del Sur S.L.
Av. Umbrete, 58,
41110 Bollullos de la Mitación, Sevilla

Sede Madrid

Calle de Zurbano, 45, 28010 Madrid

CENTRAL

Pol. PIBO. Avda. de Gines, 14
+34 955 776 767 /+34 692 454 913
41110 Bollullos de la Mitación (Sevilla)

DELEGACIÓN MADRID

+34 674 575 115
28010 Madrid

Enlaces de interés

  • Aviso Legal
  • Política de privacidad
  • Política de cookies
  • Contacto

© 2023 Distefar del Sur SL. Todos los derechos reservados. agencianodo.com

  • Contact
  • Private Zone
  • Español
  • English

    [recaptcha]

    In accordance with the provisions of Regulation (EU) 2016/679 and Organic Law 3/2018 regarding Data Protection, we inform you that the data you provide in this form will be incorporated into a file owned by DISTEFAR DEL SUR, SL domiciled in the C / Umbrete 58, (Pol. Ind. Pibo), 41110 of Bollullos de la Mitación (Seville), in order to manage your request.

    In this regard, and if you wish to exercise your rights of access, rectification, cancellation, opposition, portability and limitation, please send a written communication to DISTEFAR DEL SUR, SL, to the address indicated above or to info@distefar.com, attaching copy of your National Identity Document or equivalent identification document.

    Basic information about Data Protection

     Epigraph

    Basic information Data Protection

    Responsable

    DISTEFAR DEL SUR, S.L.

    Purpose

    Process your inquiry / request
    Detailed information on Data Protection

    Legitimation

    Consent
    Detailed information on Data Protection

    Recipients

    It is not expected to carry out data communications to third parties, except legal obligation
    Transfers of data to third countries outside the European Union will not be carried out
    Detailed information on Data Protection

    Rights

    You have the right of access, rectification, deletion, portability of your data, as well as limitation or opposition to your treatment, as detailed in Detailed information on Data Protection

    Additional Information

    You can consult the additional and detailed information on data protection by clicking here Detailed information on Data Protection

    All the data requested / The fields marked with * in the form are mandatory, if not filled in DISTEFAR DEL SUR, S.L. will not be able to meet your request.